Adult Dosing
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 2 mg intravitreally q4 wks x3 months; then 2 mg q8 wks
Notes:- Use this drug for ophthalmic intravitreal injection only
- Though this drug may be dosed as regularly as 2 mg q4 wk; additional effectiveness have not been demonstrated when this drug was dosed q4 wks vs. q8 wks
Macular edema following central retinal vein occlusion (CRVO)
- 2 mg intravitreally once q4 wks
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Endophthalmitis and retinal detachments are associated with intravitreal injections. Instruct patients to report symptoms suggestive of endophthalmitis or retinal detachment without delay and appropriately manage such symptoms. Always use proper aseptic injection technique while administration of this drug
- Acute increase in intraocular pressure (IOP) may occur following 1 hr of intravitreal injection. Sustained increase in IOP may occur following repeated intravitreal dosing with VEGF inhibitors. Monitor and appropriately manage IOP and the perfusion of the optic nerve
- Potential risk of arterial thromboembolic events (nonfatal stroke, nonfatal myocardial infarction, or vascular death including deaths of unknown cause) following intravitreal use of VEGF inhibitors exists
Caution: Use cautiously in
Supplemental Patient Information
- Advise patients to avoid driving or using machinery until temporary visual disturbances after an intravitreal injection are resolved
- Instruct patients to immediately seek care from an ophthalmologist if the eye becomes red, sensitive to light, painful, or develops a change in vision
Pregnancy Category:C
Breastfeeding: According to manufacturer a decision should be made for discontinuing nursing or discontinue the drug taking into account the importance of the drug to the mother.
